retatrutide triple hormone receptor agonist obesity Triple–Hormone-Receptor Agonist Retatrutide for — A Phase 2 Trial # First Retatrutide phase 3 data,

This effect is also observed after specific activation of GLP-1R in the NAc and most likely those receptors located on medium spiny neurons that express the dopamine-D1 receptors or dopamine-D2 receptors (Zhang et al., 2020)

Potential Side Effects Like any medical treatment, GLP-1 therapy has potential side effects that patients should be aware of

Gastrointestinal peptides bind to their receptors which are synthesized in the cell body of the NG neurons located in the neck and are transported to vagal afferent terminals in the gastrointestinal tract 11,12

Animal models of colitis have demonstrated that GLP-1 receptor activation may reduce intestinal inflammation through multiple mechanisms, including modulation of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-) and interleukin-6 (IL-6), enhancement of intestinal barrier function, and reduction of oxidative stress

Here's a quick look at what we have in store throughout the year